Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bicycle Therapeutics Plc ADR
(NQ:
BCYC
)
21.36
-0.82 (-3.70%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bicycle Therapeutics Plc ADR
< Previous
1
2
3
Next >
Bicycle Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
February 28, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Phase I Dose Escalation Results from Ongoing Phase I/II Study of BT8009
February 14, 2023
From
Bicycle Therapeutics
Via
Business Wire
Bicycle Therapeutics to Participate in the SVB Securities Global Biopharma Conference
February 08, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium
January 11, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces FDA Fast Track Designation Granted to BT8009 for the Treatment of Adult Patients with Previously Treated Locally Advanced or Metastatic Urothelial Cancer
January 04, 2023
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) Programs at the SITC 37th Annual Meeting
November 10, 2022
From
Bicycle Therapeutics
Via
Business Wire
Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update
November 08, 2022
From
Bicycle Therapeutics
Via
Business Wire
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
November 04, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 03, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Publication of Article in the Journal of Medicinal Chemistry Highlighting Preclinical Data from BT8009 Program
October 10, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT8009 Program in Molecular Cancer Therapeutics
September 19, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors
September 07, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 04, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Publication of Article in Bioconjugate Chemistry, Describing an Extension of its Proprietary Technology Platform Based on Bicyclic Peptides
August 02, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal of Medicinal Chemistry
July 12, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration
July 12, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces First Patient Dosed in Expansion Cohorts of Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors Associated with EphA2 Expression
June 08, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference
June 01, 2022
From
Bicycle Therapeutics
Via
Business Wire
Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual Meeting
May 26, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 05, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
April 11, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
April 08, 2022
From
Bicycle Therapeutics
Via
Business Wire
Bicycle Therapeutics Announces Updated Preclinical Data on SARS-CoV-2 Antivirals at the 2022 Microbiology Society Annual Meeting
April 07, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference
April 06, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Participate at the 11th Annual SVB Leerink Global Healthcare Conference
February 09, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Continued Clinical Progress and Updates to Management Team
January 05, 2022
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
November 11, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Present Four Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist™ (Bicycle TICA™) Programs at the SITC 36th Annual Meeting
November 09, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 04, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.